To our knowledge, an investigation of ATRX in cutaneous melanoma is currently lacking. Our previous studies have demonstrated that decreased expression of histone variant macroH2A drives melanoma cell proliferation and metastasis (Kapoor et al., 2010) , and that ATRX interacts with macroH2A to negatively regulate its association with chromatin (Ratnakumar et al., 2012) . Taken together with recent reports of decreased ATRX protein in neural crest cell-derived tumors, we hypothesized that ATRX function might be compromised in melanoma.
In order to test this hypothesis, we performed IHC on a panel of 23 benign nevi, 33 primary melanoma (≥1.0 mm deep) and 25 metastatic melanoma specimens that were formalin fixed paraffin embedded (FFPE) (Figure 1a , c). Slides were evaluated by two dermatopathologists in a blinded fashion using a scoring system based on number of positive nuclei and staining intensity (inter-rater correlation r=0.693, p<0.0001; see Supplemental Methods for details). As depicted in Figure 1a , ATRX protein expression is appreciably reduced with increased malignancy. Benign nevi showed a higher proportion and intensity of nuclear staining when compared to metastatic lesions (Figure 1a , b; p<0.0001). Furthermore, ATRX protein expression was reduced between benign nevi and primary melanoma, with heterogeneous staining observed in the latter (p=0.0026; Figure 1a , b), and between primary and metastatic melanoma (p=0.0113; Figure 1b ). This suggests a potential step-wise loss of ATRX expression during melanoma progression.
We further examined whether ATRX levels in primary melanoma correlated with clinicopathologic predictors of prognosis. ATRX staining did not correlate with depth of the lesion (data not shown), however the primary melanomas examined in our cohort were of Breslow thickness greater than 1.0mm (average depth 5.6 mm), and thus quite aggressive. We did however find an inverse correlation with the presence of ulceration, a poor prognostic factor (Figure 1d ). Because our study is retrospective with a small sample size, we note that any correlations, or lack thereof, are preliminary.
Because structural variations of ATRX exist in neuroblastoma and osteosarcoma (Cheung et al., 2012; Lovejoy et al., 2012) , we determined whether such alterations are present in metastatic melanoma. Using a technique to detect structural variations of ATRX, we performed qualitative reverse transcriptase (RT)-PCR of cDNA derived from a cohort of fresh frozen metastatic melanoma samples (n=7). Due to the large ATRX coding region, we amplified the cDNA into five fragments ranging from 1.5-2 kilobase pairs. Because ATRX is located on the X chromosome, we analyzed both male and female patients for potential effects due to gene dosage. Our analysis shows that the ATRX gene product is intact in all metastatic melanomas assayed, as evidenced by appropriately sized bands within each sample (Figure 2a) . The cell line WM266-4 derived from a melanoma metastasis served as a positive control for PCR amplicons, as it is devoid of ATRX mutations (Cancer Cell Line Encyclopedia at http://cbioportal.org). The osteosarcoma cell line U2OS, which has large deletions of the ATRX locus (Lovejoy et al., 2012) was used to ensure our assay worked effectively. This analysis suggested that decreased ATRX protein level in metastatic melanoma is unlikely the result of large genomic alterations.
We next queried whether diminished ATRX protein in metastatic disease was due to transcriptional regulation. We performed qPCR analysis on a cohort of 18 fresh frozen benign nevi and 20 metastatic melanoma tumors, including those samples analyzed for deletions (Figure 2a ; indicated in red in Figure 2b ). Using both N-and C-terminal primers for ATRX, we found a statistically significant loss of ATRX mRNA levels in metastatic melanoma as compared to benign tissue (p<0.0001; Figure 2b) . We next performed IHC on a subset of these tumors, for which FFPE tissue was available (indicated in blue in Figure  2b ). The level of ATRX protein indeed corroborated our qPCR findings (Figure 2c) . Collectively, these results indicate that ATRX loss occurs, at least in part, by transcriptional repression resulting in loss of protein expression in late stage disease.
Collectively, we demonstrate that ATRX loss correlates with melanoma progression. Using two independent cohorts (FFPE and fresh frozen; total of 119 tissues), we found a significant decrease of both mRNA and protein levels of ATRX in metastatic melanoma.
While it remains to be tested in a prospective study, ATRX may serve as a biomarker to predict prognosis of disease. Though we did not find evidence of large genomic alterations in a subset of melanoma patients, we do not exclude the possibility of ATRX mutations in melanoma. In fact, a 4-7.5% rate of mutation in cutaneous melanoma is reported by TCGA, Broad and Yale studies (http://www.cbioportal.org). Interestingly, these mutations are distributed throughout the ATRX coding region and do not correlate with decreased mRNA levels (Supplemental Figure S1 ). This suggests that multiple mechanisms underlie ATRX dysregulation in melanoma -transcriptional regulation as described here and point mutations that may result in loss of protein expression, as reported for other tumor types (Cheung et al., 2012; Kannan et al., 2012; Schwartzentruber et al., 2012) .
While ATRX staining did not anti-correlate with macroH2A levels (data not shown), we previously showed that macroH2A is transcriptionally silenced by DNA methylation in malignant melanoma and thus might not be regulated at the level of chromatin deposition (Kapoor et al., 2010) . The mechanism by which ATRX transcription is suppressed in melanoma may also be through epigenetic silencing (e.g. DNA methylation or histone modifications), or by microRNA mediated regulation (Pacurari et al., 2013) . Finally, we posit that investigating the chromatin landscape of tumors that have lost ATRX expression should provide insight into the mechanism(s) by which ATRX loss drives melanoma progression.
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